BCG vaccine prevents insulitis in low dose streptozotocin-induced diabetic mice

Sei-Hyun Baik, Ie Byung Park, Kyung Mook Choi, Yong Hyun Kim, Nan Hee Kim, Sang Jin Kim, Gwan Gyu Song, Dong Seop Choi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Autoimmune type 1 diabetes mellitus is caused by the immunologic destruction of pancreatic β-cells; therefore, there have been many attempts at immunologic modulation as a block or prevention of the underlying process. The aim of this study is to investigate the effect of BCG vaccination on low dose streptozotocin-induced diabetic (LDSD) mice. The mice were pretreated with BCG 7 days before starting low dose streptozotocin (STZ), observed body weight and blood glucose for 2 months, then analyzed the severity of the STZ- induced insulitis after the animals were sacrificed. In this experiment, the mean body weights in the BCG-STZ group on days 1, 19, 33, 47, and 61 of the experiment were 37.5 ± 3.6, 37.3 ± 3.6, 37.5 ± 3.5, 39.4 ± 3.9, and 39.3 ± 4.5 (g), respectively. Those in the STZ group were 37.7 ± 3.5, 38.3 ± 4.5, 38.4 ± 3.9, 36.2 ± 4.5, and 36.3 ± 4.0 (g), respectively (P < 0.05). The mean blood glucose levels in the BCG-STZ group on days 1, 19, 33, 47, and 61 were 106.5 ± 8, 150 ± 37, 147 ± 54, 143 ± 60, and 142 ± 66 (mg/dl), respectively. Those in the STZ group were 103 ± 12, 196 ± 90, 261 ± 236, 236 ± 91, and 224 ± 89 (mg/dl), respectively (P < 0.05). The numbers developing grade 0, I, II, III, and IV insulitis in the BCG-treated group were 63, 48, 33, 4, and 2, respectively, and in the control group were 16, 23, 31, 45, and 35, respectively. This study indicates that BCG vaccination reduces the development of insulitis and overt diabetes in LDSD mice.

Original languageEnglish
Pages (from-to)91-97
Number of pages7
JournalDiabetes Research and Clinical Practice
Volume46
Issue number2
DOIs
Publication statusPublished - 1999 Nov 1

Fingerprint

BCG Vaccine
Streptozocin
Mycobacterium bovis
Type 1 Diabetes Mellitus
Blood Glucose
Vaccination
Body Weight
Control Groups

Keywords

  • Autoimmune type 1 diabetes mellitus
  • BCG
  • Insulitis
  • LDSD

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

BCG vaccine prevents insulitis in low dose streptozotocin-induced diabetic mice. / Baik, Sei-Hyun; Park, Ie Byung; Choi, Kyung Mook; Kim, Yong Hyun; Kim, Nan Hee; Kim, Sang Jin; Song, Gwan Gyu; Choi, Dong Seop.

In: Diabetes Research and Clinical Practice, Vol. 46, No. 2, 01.11.1999, p. 91-97.

Research output: Contribution to journalArticle

@article{4afc198ec2a641b3bce3e577d702fd78,
title = "BCG vaccine prevents insulitis in low dose streptozotocin-induced diabetic mice",
abstract = "Autoimmune type 1 diabetes mellitus is caused by the immunologic destruction of pancreatic β-cells; therefore, there have been many attempts at immunologic modulation as a block or prevention of the underlying process. The aim of this study is to investigate the effect of BCG vaccination on low dose streptozotocin-induced diabetic (LDSD) mice. The mice were pretreated with BCG 7 days before starting low dose streptozotocin (STZ), observed body weight and blood glucose for 2 months, then analyzed the severity of the STZ- induced insulitis after the animals were sacrificed. In this experiment, the mean body weights in the BCG-STZ group on days 1, 19, 33, 47, and 61 of the experiment were 37.5 ± 3.6, 37.3 ± 3.6, 37.5 ± 3.5, 39.4 ± 3.9, and 39.3 ± 4.5 (g), respectively. Those in the STZ group were 37.7 ± 3.5, 38.3 ± 4.5, 38.4 ± 3.9, 36.2 ± 4.5, and 36.3 ± 4.0 (g), respectively (P < 0.05). The mean blood glucose levels in the BCG-STZ group on days 1, 19, 33, 47, and 61 were 106.5 ± 8, 150 ± 37, 147 ± 54, 143 ± 60, and 142 ± 66 (mg/dl), respectively. Those in the STZ group were 103 ± 12, 196 ± 90, 261 ± 236, 236 ± 91, and 224 ± 89 (mg/dl), respectively (P < 0.05). The numbers developing grade 0, I, II, III, and IV insulitis in the BCG-treated group were 63, 48, 33, 4, and 2, respectively, and in the control group were 16, 23, 31, 45, and 35, respectively. This study indicates that BCG vaccination reduces the development of insulitis and overt diabetes in LDSD mice.",
keywords = "Autoimmune type 1 diabetes mellitus, BCG, Insulitis, LDSD",
author = "Sei-Hyun Baik and Park, {Ie Byung} and Choi, {Kyung Mook} and Kim, {Yong Hyun} and Kim, {Nan Hee} and Kim, {Sang Jin} and Song, {Gwan Gyu} and Choi, {Dong Seop}",
year = "1999",
month = "11",
day = "1",
doi = "10.1016/S0168-8227(99)00079-0",
language = "English",
volume = "46",
pages = "91--97",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - BCG vaccine prevents insulitis in low dose streptozotocin-induced diabetic mice

AU - Baik, Sei-Hyun

AU - Park, Ie Byung

AU - Choi, Kyung Mook

AU - Kim, Yong Hyun

AU - Kim, Nan Hee

AU - Kim, Sang Jin

AU - Song, Gwan Gyu

AU - Choi, Dong Seop

PY - 1999/11/1

Y1 - 1999/11/1

N2 - Autoimmune type 1 diabetes mellitus is caused by the immunologic destruction of pancreatic β-cells; therefore, there have been many attempts at immunologic modulation as a block or prevention of the underlying process. The aim of this study is to investigate the effect of BCG vaccination on low dose streptozotocin-induced diabetic (LDSD) mice. The mice were pretreated with BCG 7 days before starting low dose streptozotocin (STZ), observed body weight and blood glucose for 2 months, then analyzed the severity of the STZ- induced insulitis after the animals were sacrificed. In this experiment, the mean body weights in the BCG-STZ group on days 1, 19, 33, 47, and 61 of the experiment were 37.5 ± 3.6, 37.3 ± 3.6, 37.5 ± 3.5, 39.4 ± 3.9, and 39.3 ± 4.5 (g), respectively. Those in the STZ group were 37.7 ± 3.5, 38.3 ± 4.5, 38.4 ± 3.9, 36.2 ± 4.5, and 36.3 ± 4.0 (g), respectively (P < 0.05). The mean blood glucose levels in the BCG-STZ group on days 1, 19, 33, 47, and 61 were 106.5 ± 8, 150 ± 37, 147 ± 54, 143 ± 60, and 142 ± 66 (mg/dl), respectively. Those in the STZ group were 103 ± 12, 196 ± 90, 261 ± 236, 236 ± 91, and 224 ± 89 (mg/dl), respectively (P < 0.05). The numbers developing grade 0, I, II, III, and IV insulitis in the BCG-treated group were 63, 48, 33, 4, and 2, respectively, and in the control group were 16, 23, 31, 45, and 35, respectively. This study indicates that BCG vaccination reduces the development of insulitis and overt diabetes in LDSD mice.

AB - Autoimmune type 1 diabetes mellitus is caused by the immunologic destruction of pancreatic β-cells; therefore, there have been many attempts at immunologic modulation as a block or prevention of the underlying process. The aim of this study is to investigate the effect of BCG vaccination on low dose streptozotocin-induced diabetic (LDSD) mice. The mice were pretreated with BCG 7 days before starting low dose streptozotocin (STZ), observed body weight and blood glucose for 2 months, then analyzed the severity of the STZ- induced insulitis after the animals were sacrificed. In this experiment, the mean body weights in the BCG-STZ group on days 1, 19, 33, 47, and 61 of the experiment were 37.5 ± 3.6, 37.3 ± 3.6, 37.5 ± 3.5, 39.4 ± 3.9, and 39.3 ± 4.5 (g), respectively. Those in the STZ group were 37.7 ± 3.5, 38.3 ± 4.5, 38.4 ± 3.9, 36.2 ± 4.5, and 36.3 ± 4.0 (g), respectively (P < 0.05). The mean blood glucose levels in the BCG-STZ group on days 1, 19, 33, 47, and 61 were 106.5 ± 8, 150 ± 37, 147 ± 54, 143 ± 60, and 142 ± 66 (mg/dl), respectively. Those in the STZ group were 103 ± 12, 196 ± 90, 261 ± 236, 236 ± 91, and 224 ± 89 (mg/dl), respectively (P < 0.05). The numbers developing grade 0, I, II, III, and IV insulitis in the BCG-treated group were 63, 48, 33, 4, and 2, respectively, and in the control group were 16, 23, 31, 45, and 35, respectively. This study indicates that BCG vaccination reduces the development of insulitis and overt diabetes in LDSD mice.

KW - Autoimmune type 1 diabetes mellitus

KW - BCG

KW - Insulitis

KW - LDSD

UR - http://www.scopus.com/inward/record.url?scp=0344069775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344069775&partnerID=8YFLogxK

U2 - 10.1016/S0168-8227(99)00079-0

DO - 10.1016/S0168-8227(99)00079-0

M3 - Article

C2 - 10724086

AN - SCOPUS:0344069775

VL - 46

SP - 91

EP - 97

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -